Telotristat Etiprate

N/A

Report date: 2024/08/02 17:36:07
NMEFirst In Class

Base Information

Drug NameTelotristat Etiprate
Drug Alias Nametelotristat ethylXermeloLX-1606LX-1032
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTryptophan hydroxylase 2 inhibitorsTryptophan hydroxylase 1 inhibitors
TargetsTryptophan hydroxylase 2Tryptophan hydroxylase 1
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyColitis, Ulcerative +[7] 
Global Approved IndicationsMalignant Carcinoid SyndromeCarcinoid TumorNeuroendocrine Tumors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/02/28
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLexicon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSerb SasThe University Of Texas MD Anderson Cancer CenterTersera Therapeutics Llc
Inactive CompaniesIpsenBarbara Ann Karmanos Cancer InstituteThe University Of Chicago +[4] 
Active IndicationsMalignant Carcinoid SyndromeCarcinoid TumorNeuroendocrine Tumors
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyColitis, Ulcerative +[4] 

Other Information

ATC CodeA16A
Related LinksWikipediaDrugBankKEGG